Similarly, to the previously observation in MM cell lines, when BM plasma cells were labeled simultaneously with both biotinylated isatuximab and daratumumab, these antibodies did not compete for the CD38 binding site (Figure 1C). The gene discussed is CD38; the disease is Miyoshi myopathy.